KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Gains from Sales and Divestitures (2019)

Historic Gains from Sales and Divestitures for Amneal Pharmaceuticals (AMRX) over the last 1 years, with Q4 2019 value amounting to $479299.0.

  • Amneal Pharmaceuticals' Gains from Sales and Divestitures changed N/A to $479299.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $479299.0, marking a year-over-year change of. This contributed to the annual value of $479299.0 for FY2019, which is N/A changed from last year.
  • As of Q4 2019, Amneal Pharmaceuticals' Gains from Sales and Divestitures stood at $479299.0.
  • In the past 5 years, Amneal Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $479299.0 in Q4 2019 and a low of $479299.0 during Q4 2019